Mabwell (Shanghai) Bioscience Co., Ltd. (SHA:688062)

Market Cap	13.66B +106.9%
Revenue (ttm)	662.52M +231.6%
Net Income	-970.18M
EPS	-2.43
Shares Out	399.40M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,455,530
Average Volume	5,673,379
Open	32.30
Previous Close	32.27
Day's Range	32.22 - 34.36
52-Week Range	16.71 - 63.59
Beta	0.91
RSI	42.08
Earnings Date	Mar 25, 2026

About SHA:688062

Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacture, and commercialization of biological products for oncology, immunology, bone disorders, ophthalmology, hematology, and infectious diseases in China and internationally. The company offers MAIWEIJIAN for the treatment of giant cell tumor of bone; MALISHU for the treatment of postmenopausal women with osteoporosis; and JUNMAIKANG, an autoimmune Adalimumab injection. Its oncology product pipeline includes 9MW2821, a Nectin-4 t...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 1,362
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688062

Financial Performance

In 2025, SHA:688062's revenue was 662.52 million, an increase of 231.62% compared to the previous year's 199.78 million. Losses were -970.18 million, -7.06% less than in 2024.